CME 9 Session – EANM’13

Brain PET Imaging

Educational objectives:
  1. Review the criteria for reading brain PET images using 18F-FDG; 18F-DOPA, radiolabelled amino acid analogues and amyloid plaques tracers (18F-FET?)
  2. Identify the possible difficulties and pitfalls
  3. Understand the relevance of multidimensional information: clinical, biological, neuropsychological and neuroradiological
Imaging of the brain is becoming the second most common indication of PET imaging. This CME session is directed primarily to nuclear physician who want to improve their knowledge about this topic. The session will address brain imaging with 18F-FDG; 18F-DOPA, radiolabelled amino acid analogues (11C-Methionine and 18F compounds as 18F-FET and 18F-DOPA) and amyloid plaques markers. It will consist in interactive clinical cases presentation. Voting systems will allow the attendees to express their opinion and to test their skills.
Common and less common forms of neurodegenerative diseases will be presented. Imaging and clinical overlaps will be shown in order to illustrate how reading relies on the knowledge of multidimensional information. This part will include dementias and Parkinson disease using 18F-FDG and 18F-DOPA. Amyloid plaques imaging will also be addressed focusing on image acquisition, reading criteria and on the use of the corresponding information in patients’ management.
For brain tumour imaging, cases will illustrate how radiolabelled amino acid analogues can add important information for patient management. Mutlimodal imaging including MRI will be described as well as the advantages and limitations of 18F-FDG in that field.

Key Words:
PET, Brain Imaging, Dementia, Parkinson, Brain Tumours

Extended Abstract Book for download (5 MB)

User action required
If you have the permission to view this publication, please log in.